Replies to post #345907 on Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

I agree this could be a template for a future deal. If Brilacidin does become the Covid19 antiviral drug of choice it will be worth much more than OncoImmune's CD24Fc and Gilead's Remdesivir.

Remdesivir brought in almost 2 billion dollars last quarter. A lot of money for a drug many clinicians and the WHO says doesn't work or at best is mildly effective.

"Remdesivir, which is sold under the brand name Veklury, brought in $1.9 billion in the fourth quarter ended Dec. 31, above analysts’ estimates of $1.34 billion. Excluding Veklury, Gilead said its quarterly sales fell 7%."

"For 2021, the California-based company projected an adjusted earnings range with a midpoint of $7.10 per share, on product sales with a midpoint of $24.4 billion, ahead of respective Wall Street estimates of $6.85 per share and $24.27 billion, according to IBES data from Refinitiv."

https://www.reuters.com/article/us-gilead-sciences-results/gilead-forecasts-2021-growth-strong-remdesivir-covid-19-sales-idUSKBN2A42V7

https://www.bmj.com/content/371/bmj.m4057

[thefamilyman]

I think you may have missed some of my posts because I have certainly addressed this point.

Petemantx said,

I push this point often as I have not seen many (if anyone) making the strong point that BP shouldn't be given a carte blanche super percentage of the revenues with no clauses that escalate greatly the percentage IPIX reaps as revenues increase for our drugs.

Here’s one of my previous posts from 2/9/21...

After the Covid crisis has passed, I could see Leo signing with a BP to develop Brilacidin for innumerable diseases (bacterial, virus, parasitic, IBD, and perhaps even fungal or other conditions). But hopefully Leo is smart enough to negotiate a sliding scale of royalties that gets us to 50% after the gross reaches a billion or so.

I posted this on 2/9/21 in response to a post from HereToday proposing only 20% royalty...

20%? Absolutely not! If Brilacidin works against Covid, the governments of the world are going to write very large checks THIS YEAR. A big upfront payment is not worth much when the gross is going to dwarf the upfront payment in the short term. And giving 80% of the revenue to a “partner” who did NOTHING to get us to this point is an insult. Again, if Brilacidin works, we do NOT need a BP “partner”. We already contract the production and the finished product can be direct shipped to the appropriate address. All that remains is to deposit the checks (or just confirm that the proper funding was wired into our account).

[Lemoncat]

Your royalty is way out of the norm and will never happen. Times aren't that different for big pharma. We need them more than they need us.

IPIX will need a partnership to get EUA. The FDA is captured and will not disrupt big pharma revenue streams by letting an OTC company immediately join the fray and take all the government money.

What we would hand them is hardly a finished product. Big pharma will need to ramp manufacturing, coordinate distribution/contracts, and pull the appropriate levers to get approvals. IPIX does not have this capability.

It's the golden rule: he who has the gold makes the rules.

I'll consider any near term monetization of the COVID indication that secures development of the rest of the pipeline and puts all shareholders in the green to be a massive, unforeseen victory by Leo.

Go IPIX!